Products

Image description

FDA approves GSK's Promacta for treatment of SAA

GlaxoSmithKline announced that the Food and Drug Administration approved its supplemental new drug application for Promacta (eltrombopag), a once-daily medication for patients with severe aplastic anaemia who have had an insufficient response to immunosuppressive therapy.